Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

61. Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Grössmann N Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions The treatment of nivolumab offers durable responses, 31.1% demonstrated

Health Technology Assessment (HTA) Database.2017

62. OPDIVO - Nivolumab

OPDIVO - Nivolumab Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include post-authorization

Health Canada - Drug and Health Product Register2017

64. Nivolumab for the treatment of renal-cell carcinoma

Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, López A, Pichon (...) -Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L. Nivolumab for the treatment of renal-cell carcinoma. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 491. 2016 Authors' conclusions No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage. High-quality evidence, coming from a single study in patients with clear cell histology, indicates

Health Technology Assessment (HTA) Database.2016

65. Nivolumab (Opdivo) - as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Nivolumab (Opdivo) - as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Scottish Medicines Consortium2016

67. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line

Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSRIC. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Nivolumab and ipilimumab are two drugs used to treat renal cell carcinoma, which is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Nivolumab

Health Technology Assessment (HTA) Database.2016

68. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial 27622997 2016 09 13 2017 02 03 1474-5488 17 11 2016 Nov The Lancet. Oncology Lancet Oncol. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 1558-1568 S1470-2045(16)30366-7 10.1016 (...) /S1470-2045(16)30366-7 Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma

EvidenceUpdates2016

69. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35. [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2016

70. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Cologne

Health Technology Assessment (HTA) Database.2016

71. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Cologne

Health Technology Assessment (HTA) Database.2016

72. Nivolumab (Opdivo) - treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Nivolumab (Opdivo) - treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Scottish Medicines Consortium2016

78. Nivolumab (Opdivo) for treatment of non-small cell lung cancer

Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for treatment of non-small cell lung cancer. Lansdale: HAYES, Inc.. Healthcare (...) Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based

Health Technology Assessment (HTA) Database.2016

79. [Nivolumab - addendum to commission A15-32]

[Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab: addendum zum auftrag A15-32; auftrag A15-58. [Nivolumab - addendum to commission A15-32] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 356. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Programmed Cell Death 1 Receptor Language Published German Country of organisation Germany English

Health Technology Assessment (HTA) Database.2016

80. Nivolumab for follicular non-Hodgkin lymphoma Ä third line

Nivolumab for follicular non-Hodgkin lymphoma Ä third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab for follicular non-Hodgkin lymphoma ─ third line. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2016 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. It often progresses slowly, with patients showing no symptoms for many years. Nivolumab is a new antibody drug for the treatment of follicular lymphoma that is delivered straight into the bloodstream via a drip. Some studies have

Health Technology Assessment (HTA) Database.2016